Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Faucard R, Madeira A, Gehin N, Authier FJ, Panaite PA, Lesage C, Burgelin I, Bertel M, Bernard C, Curtin F, Lang AB, Steck AJ, Perron H, Kuntzer T, Créange A.

EBioMedicine. 2016 Apr;6:190-198. doi: 10.1016/j.ebiom.2016.03.001. Epub 2016 Mar 10.

2.

Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study.

Curtin F, Vidal V, Bernard C, Kromminga A, Lang AB, Porchet H.

MAbs. 2016 Jul;8(5):854-60. doi: 10.1080/19420862.2016.1168956. Epub 2016 Mar 30.

3.

MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.

Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R.

J Neuroimmunol. 2016 Feb 15;291:29-38. doi: 10.1016/j.jneuroim.2015.12.006. Epub 2015 Dec 11.

4.

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.

Zimmermann M, Sanderson NS, Rasenack M, Lalive PH, Lang AB, Curtin F, Lindberg RL, Kappos L, Derfuss T.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e144. doi: 10.1212/NXI.0000000000000144. eCollection 2015 Oct.

5.

Treatment against human endogenous retrovirus: a possible personalized medicine approach for multiple sclerosis.

Curtin F, Perron H, Faucard R, Porchet H, Lang AB.

Mol Diagn Ther. 2015 Oct;19(5):255-65. doi: 10.1007/s40291-015-0166-z.

PMID:
26376649
6.

ER-mitochondrial junctions can be bypassed by dominant mutations in the endosomal protein Vps13.

Lang AB, John Peter AT, Walter P, Kornmann B.

J Cell Biol. 2015 Sep 14;210(6):883-90. doi: 10.1083/jcb.201502105.

7.

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

J Neuroimmunol. 2015 Aug 15;285:68-70. doi: 10.1016/j.jneuroim.2015.05.019. Epub 2015 May 20.

PMID:
26198921
8.

Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.

Curtin F, Perron H, Kromminga A, Porchet H, Lang AB.

MAbs. 2015;7(1):265-75. doi: 10.4161/19420862.2014.985021.

9.

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

Mult Scler. 2015 Jun;21(7):885-93. doi: 10.1177/1352458514554052. Epub 2014 Nov 12.

PMID:
25392325
10.

Human monoclonal antibodies as a new class of antiinfective compounds.

Burioni R, Lang AB, Capra JD.

Clin Dev Immunol. 2013;2013:297120. doi: 10.1155/2013/297120. Epub 2013 Sep 11. No abstract available.

11.

Re: Errors in the editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670-1672].

Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Vander-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP.

Mult Scler. 2013 May;19(6):831-2. doi: 10.1177/1352458513485150. No abstract available.

PMID:
23658240
12.

GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.

Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP.

Clin Ther. 2012 Dec;34(12):2268-78. doi: 10.1016/j.clinthera.2012.11.006. Epub 2012 Nov 29.

PMID:
23200102
13.

Probing real sensory worlds of receivers with unsupervised clustering.

Pfeiffer M, Hartbauer M, Lang AB, Maass W, Römer H.

PLoS One. 2012;7(6):e37354. doi: 10.1371/journal.pone.0037354. Epub 2012 Jun 6.

14.

Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.

Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP.

Mult Scler. 2012 Dec;18(12):1721-36. doi: 10.1177/1352458512441381. Epub 2012 Mar 28.

15.

Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Horn MP, Zuercher AW, Imboden MA, Rudolf MP, Lazar H, Wu H, Hoiby N, Fas SC, Lang AB.

Antimicrob Agents Chemother. 2010 Jun;54(6):2338-44. doi: 10.1128/AAC.01142-09. Epub 2010 Mar 22.

16.

Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers.

Lazar H, Horn MP, Zuercher AW, Imboden MA, Durrer P, Seiberling M, Pokorny R, Hammer C, Lang AB.

Antimicrob Agents Chemother. 2009 Aug;53(8):3442-6. doi: 10.1128/AAC.01699-08. Epub 2009 May 18.

17.

Endogenous retroviral genes, Herpesviruses and gender in Multiple Sclerosis.

Perron H, Bernard C, Bertrand JB, Lang AB, Popa I, Sanhadji K, Portoukalian J.

J Neurol Sci. 2009 Nov 15;286(1-2):65-72. doi: 10.1016/j.jns.2009.04.034. Epub 2009 May 17. Review.

PMID:
19447411
18.

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.

Zuercher AW, Horn MP, Que JU, Ruedeberg A, Schoeni MH, Schaad UB, Marcus P, Lang AB.

FEMS Immunol Med Microbiol. 2006 Jul;47(2):302-8.

19.

Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa.

Zuercher AW, Horn MP, Wu H, Song Z, Bundgaard CJ, Johansen HK, Høiby N, Marcus P, Lang AB.

Vaccine. 2006 May 15;24(20):4333-42. Epub 2006 Mar 20.

PMID:
16600444
20.

Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Zuercher AW, Imboden MA, Jampen S, Bosse D, Ulrich M, Chtioui H, Lauterburg BH, Lang AB.

Clin Exp Immunol. 2006 Jan;143(1):132-8.

21.

Activity levels of bats and katydids in relation to the lunar cycle.

Lang AB, Kalko EK, Römer H, Bockholdt C, Dechmann DK.

Oecologia. 2006 Jan;146(4):659-66. Epub 2005 Nov 5.

PMID:
16273422
22.

Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Zuercher AW, Imboden MA, Jampen S, Bosse D, Ulrich M, Chtioui H, Lauterburg BH, Lang AB.

Clin Exp Immunol. 2005 Nov;142(2):381-7.

23.

Immunisation in the current management of cystic fibrosis patients.

Malfroot A, Adam G, Ciofu O, Döring G, Knoop C, Lang AB, Van Damme P, Dab I, Bush A; European Cystic Fibrosis Society (ECFS) Vaccination Group.

J Cyst Fibros. 2005 May;4(2):77-87.

24.

Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients.

Lang AB, Horn MP, Imboden MA, Zuercher AW.

Vaccine. 2004 Dec 6;22 Suppl 1:S44-8.

PMID:
15576201
25.

B cells alter the phenotype and function of follicular-homing CXCR5+ T cells.

Ebert LM, Horn MP, Lang AB, Moser B.

Eur J Immunol. 2004 Dec;34(12):3562-71.

26.

Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.

Lang AB, Rüdeberg A, Schöni MH, Que JU, Fürer E, Schaad UB.

Pediatr Infect Dis J. 2004 Jun;23(6):504-10.

PMID:
15194830
27.

Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

Durrer P, Glück U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Glück R.

Vaccine. 2003 Oct 1;21(27-30):4328-34.

PMID:
14505915
28.

Flexible migration program regulates gamma delta T-cell involvement in humoral immunity.

Brandes M, Willimann K, Lang AB, Nam KH, Jin C, Brenner MB, Morita CT, Moser B.

Blood. 2003 Nov 15;102(10):3693-701. Epub 2003 Jul 24.

29.

Experience with registered mucosal vaccines.

Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret JF.

Vaccine. 2003 Jan 30;21(7-8):678-83. Review.

PMID:
12531339
30.

CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function.

Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B.

J Exp Med. 2000 Dec 4;192(11):1553-62.

31.
32.
33.
34.

Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.

Schwarzer S, Reibel S, Lang AB, Struck MM, Finkel B, Gerike E, Tischer A, Gassner M, Glück R, Stück B, Cryz SJ Jr.

Vaccine. 1998 Jan-Feb;16(2-3):298-304.

PMID:
9607046
35.

Protein transport across the in vitro perfused human placenta.

Malek A, Sager R, Lang AB, Schneider H.

Am J Reprod Immunol. 1997 Oct;38(4):263-71.

PMID:
9352013
36.

Role of repetitive antigen patterns for induction of antibodies against antibodies.

Fehr T, Bachmann MF, Bucher E, Kalinke U, Di Padova FE, Lang AB, Hengartner H, Zinkernagel RM.

J Exp Med. 1997 May 19;185(10):1785-92.

37.

Culture and IgE synthesis of nasal B cells.

Zürcher AW, Derer T, Lang AB, Stadler BM.

Int Arch Allergy Immunol. 1996 Sep;111(1):77-82.

PMID:
8753848
38.
39.

Polyclonal preparations of anti-tetanus toxoid antibodies derived from a combinatorial library confer protection.

Lang AB, Vogel M, Viret JF, Stadler BM.

Biotechnology (N Y). 1995 Jul;13(7):683-5.

PMID:
9634805
40.

IgE-producing hybridomas established after B-cell culture in the CD40 system.

Zürcher AW, Lang AB, Aebischer I, Miescher S, Stadler BM.

Immunol Lett. 1995 May;46(1-2):49-57.

PMID:
7590927
41.

Human monoclonal or polyclonal antibodies recognize predominantly discontinuous epitopes on bee venom phospholipase A2.

Schneider T, Lang AB, Carballido JM, Santamaria Babi LF, Dudler T, Kägi MK, Blaser K, Suter M.

J Allergy Clin Immunol. 1994 Jul;94(1):61-70.

PMID:
7517969
42.

Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa.

Cryz SJ Jr, Wedgwood J, Lang AB, Ruedeberg A, Que JU, Fürer E, Schaad UB.

J Infect Dis. 1994 May;169(5):1159-62.

PMID:
8169414
43.

Affinities of endotoxin-specific human monoclonal antibodies, their polyclonal counterparts and murine monoclonal antibodies.

Bruderer U, Deusinger M, Schürch U, Lang AB.

Res Immunol. 1993 Nov-Dec;144(9):659-65.

PMID:
8159868
44.
45.

Feasibility of prophylaxis and therapy against gram-negative infections by human monoclonal antibodies.

Lang AB, Fürer E, Cryz SJ Jr.

FEMS Immunol Med Microbiol. 1993 Jun;7(1):9-13.

PMID:
8364527
47.

Therapeutic human antibodies derived from PCR amplification of B-cell variable regions.

Larrick JW, Wallace EF, Coloma MJ, Bruderer U, Lang AB, Fry KE.

Immunol Rev. 1992 Dec;130:69-85.

PMID:
1286873
48.

Selective generation of antigen-specific human hybridomas optimized for large scale growth in serum-free medium.

Lang AB, Schürch U, Zimmermann F, Bruderer U.

J Immunol Methods. 1992 Sep 18;154(1):21-6.

PMID:
1401940
49.

Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.

Bruderer U, Cryz SJ Jr, Schaad UB, Deusinger M, Que JU, Lang AB.

J Infect Dis. 1992 Aug;166(2):344-9.

PMID:
1634805
50.

Supplemental Content

Support Center